人急性淋巴细胞白血病细胞系的研究进展  

Progress in acute lymphoblastic leukemia cell lines

作　　者：王倩(综述)[1] 许小平(审校)[1] 

机构地区：[1]复旦大学附属华山医院血液科,上海200040

出　　处：《白血病．淋巴瘤》2016年第8期501-505,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81070404、81100389）;国家科技重大专项子课题（2012ZX09303004-001）

摘　　要：急性淋巴细胞白血病（ALL）是一组来自B系或T系淋巴前体细胞的恶性克隆性疾病.ALL不仅在儿童急性白血病中最为常见,亦占成年人急性白血病的20％,其恶性程度高,治疗效果差,缓解率低.有关生物学特性及药理学的研究对改善ALL患者生存率及提高生命质量具有重要作用.来源于ALL患者的人ALL细胞系为探索ALL的发生、演变机制和相关药物研发提供了不可替代的细胞模型.目前已建立的人ALL细胞系几乎涵盖大部分ALL的免疫分型及特异性染色体异常,对推动ALL遗传学诊断及靶向治疗进展起到重要作用.文章对人ALL细胞系的建系进展,尤其是携带费城染色体及MLL基因重排的人ALL细胞系进行综述.Acute lymphoblastic leukemia （ALL） is a malignant clonal disease deriving from B or T lineage lymphoid precursors.ALL characterized by its high malignancy,poor curative effect and low remission rate occurs most frequently in pediatrics,but also accounts for 20 % of leukemia in adult.The further study of the biological feature and pharmacology may play a significant role in the improvement of the survival rate and life quality for ALL patients.The advent of continuous human ALL cell lines provides irreplacable cell-model for the occurrence,evolvement mechanism and drugs research in ALL.Besides,ALL cell lines established at present have covered most of the immunophenotyping and specificity chromosome abnormality,which promote the progress of genetics diagnosis and target therapy.This paper will review the advances in ALL cell lines,especially the cell lines with Ph chromosome and MLL gene alterations.

关 键 词：白血病 淋巴细胞 急性 细胞系 费城染色体 基因 MLL 

分 类 号：R733.71[医药卫生—肿瘤]